QOL Medical and Its CEO Agree To Pay $47 Million for Allegedly Paying Kickbacks To Induce Claims for QOL's Drug Sucraid
BOSTON – Pharmaceutical company QOL Medical, LLC (QOL) and its CEO, Frederick E. Cooper, have agreed to pay $47 million to resolve allegations that they caused the submission of false claims to federal health care programs, in violation of the False Claims Act, by offering kickbacks, in the form of free Carbon-13 breath testing services, to induce claims for QOL’s drug Sucraid.
Action Details
- Date:November 15, 2024
- Agency:U.S. Attorney's Office, District of Massachusetts
-
Enforcement Types:
- Criminal and Civil Actions